Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
44
NCT00907205
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2007
Completion: Apr 30, 2011